$0.01
9.03% yesterday
Nasdaq, Sep 15, 09:52 pm CET
ISIN
US30048L1044
Symbol
EVFM

Evofem Biosciences, Inc. Stock price

$0.02
+0.01 61.70% 1M
+0.01 90.00% 6M
+0.01 53.54% YTD
+0.01 58.33% 1Y
-37.83 99.96% 3Y
-4,087.48 100.00% 5Y
-132,524.98 100.00% 10Y
-134,999.98 100.00% 20Y
Nasdaq, Closing price Mon, Sep 15 2025
-0.00 1.94%
ISIN
US30048L1044
Symbol
EVFM
Industry

Key metrics

Basic
Market capitalization
$1.8m
Enterprise Value
$47.2m
Net debt
$45.3m
Cash
$350.0k
Shares outstanding
113.4m
Valuation (TTM | estimate)
P/E
- | -
P/S
0.1 | -
EV/Sales
2.8 | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-279.4%
Return on Equity
13.5%
ROCE
7.8%
ROIC
67.1%
Debt/Equity
-0.7
Financials (TTM | estimate)
Revenue
$16.6m | -
EBITDA
$-3.7m | -
EBIT
$-4.5m | -
Net Income
$-3.2m | -
Free Cash Flow
$-3.5m
Growth (TTM | estimate)
Revenue
3.8% | -
EBITDA
78.3% | -
EBIT
73.7% | -
Net Income
-106.7% | -
Free Cash Flow
12.0%
Margin (TTM | estimate)
Gross
78.8%
EBITDA
-22.1% | -
EBIT
-27.1%
Net
-19.0% | -
Free Cash Flow
-20.8%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
11.0%
Employees
32
Rev per Employee
$610.0k
Show more

Is Evofem Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Evofem Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Evofem Biosciences, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Evofem Biosciences, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Evofem Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
17 17
4% 4%
100%
- Direct Costs 3.52 3.52
40% 40%
21%
13 13
28% 28%
79%
- Selling and Administrative Expenses 21 21
16% 16%
124%
- Research and Development Expense 1.25 1.25
58% 58%
8%
-3.66 -3.66
78% 78%
-22%
- Depreciation and Amortization 0.84 0.84
250% 250%
5%
EBIT (Operating Income) EBIT -4.51 -4.51
74% 74%
-27%
Net Profit -3.16 -3.16
107% 107%
-19%

In millions USD.

Don't miss a Thing! We will send you all news about Evofem Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evofem Biosciences, Inc. Stock News

Neutral
PRNewsWire
4 days ago
-- 130% increase in traffic to PHEXXI.com, the website for Evofem's hormone-free prescription contraceptive PHEXXI® (lactic acid citric acid and potassium bitartrate) -- -- PHEXXI® is #1 most followed contraceptive brand on social media by healthcare providers -- SAN DIEGO , Sept. 11, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (Evofem) (OTCID: EVFM) today announced the conclusion and excitin...
Neutral
PRNewsWire
6 days ago
-- Special Meeting to be held on September 26, 2025 -- SAN DIEGO , Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID: EVFM) anticipates the approval of the transactions (the "Merger") contemplated by the Amended and Restated Merger Agreement dated as of July 12, 2024, as amended, (collectively, the "Merger Agreement"), ...
Neutral
PRNewsWire
26 days ago
-- Passage of House Bill 3489 allows Illinois pharmacists to prescribe non-hormonal and emergency contraceptives -- -- Ensures a broader range of contraceptive choices is available to women state-wide -- SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- On August 15, 2025, Illinois enacted House Bill 3489, a measure designed to broaden access to contraception for its residents. This legislation permits...
More Evofem Biosciences, Inc. News

Company Profile

Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women. Its product include Amphora Contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections and Antimicrobial Drug product to prevent the reoccurrence of bacterial vaginosis. The company was founded in 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Saundra Pelletier
Employees 32
Founded 2007
Website www.evofem.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today